Sana Biotechnology Inc (SANA)
8.715
+0.16
(+1.93%)
USD |
NASDAQ |
May 17, 16:00
8.715
0.00 (0.00%)
After-Hours: 20:00
Sana Biotechnology Enterprise Value: 1.623B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.623B |
| May 16, 2024 | 1.583B |
| May 15, 2024 | 1.742B |
| May 14, 2024 | 1.594B |
| May 13, 2024 | 1.441B |
| May 10, 2024 | 1.363B |
| May 09, 2024 | 1.350B |
| May 08, 2024 | 1.791B |
| May 07, 2024 | 1.913B |
| May 06, 2024 | 1.904B |
| May 03, 2024 | 2.001B |
| May 02, 2024 | 1.853B |
| May 01, 2024 | 1.820B |
| April 30, 2024 | 1.681B |
| April 29, 2024 | 1.699B |
| April 26, 2024 | 1.619B |
| April 25, 2024 | 1.570B |
| April 24, 2024 | 1.588B |
| April 23, 2024 | 1.479B |
| April 22, 2024 | 1.444B |
| April 19, 2024 | 1.373B |
| April 18, 2024 | 1.400B |
| April 17, 2024 | 1.517B |
| April 16, 2024 | 1.550B |
| April 15, 2024 | 1.581B |
| Date | Value |
|---|---|
| April 12, 2024 | 1.672B |
| April 11, 2024 | 1.761B |
| April 10, 2024 | 1.681B |
| April 09, 2024 | 1.756B |
| April 08, 2024 | 1.701B |
| April 05, 2024 | 1.683B |
| April 04, 2024 | 1.572B |
| April 03, 2024 | 1.716B |
| April 02, 2024 | 1.641B |
| April 01, 2024 | 1.928B |
| March 28, 2024 | 1.999B |
| March 27, 2024 | 1.999B |
| March 26, 2024 | 1.880B |
| March 25, 2024 | 1.799B |
| March 22, 2024 | 1.812B |
| March 21, 2024 | 1.812B |
| March 20, 2024 | 1.768B |
| March 19, 2024 | 1.702B |
| March 18, 2024 | 1.759B |
| March 15, 2024 | 1.752B |
| March 14, 2024 | 1.790B |
| March 13, 2024 | 1.966B |
| March 12, 2024 | 1.838B |
| March 11, 2024 | 1.889B |
| March 08, 2024 | 1.889B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
122.67M
Minimum
Dec 27 2022
7.771B
Maximum
Feb 10 2021
1.552B
Average
878.99M
Median
Jul 17 2023
Enterprise Value Benchmarks
| Rocket Pharmaceuticals Inc | 1.723B |
| Solid Biosciences Inc | 137.43M |
| Dyne Therapeutics Inc | 1.965B |
| Taysha Gene Therapies Inc | 494.42M |
| Tenaya Therapeutics Inc | 243.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -107.48M |
| Total Expenses (Quarterly) | 110.72M |
| EPS Diluted (Quarterly) | -0.49 |
| Earnings Yield | -17.53% |